Hercules Capital, Inc. — Q1 2024 Form 10-Q
Business and period: Specialty finance company and BDC focused on senior secured lending to venture- and institutionally backed businesses, particularly in technology, life sciences, and related sectors. This unaudited report covers the three months ended March 31, 2024; balance-sheet comparisons are to December 31, 2023.
Key financial results
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Total investment income | $121.6 million | $105.1 million |
| Net investment income | $79.2 million; $0.50 per share | $65.5 million; $0.48 per share |
| Net realized gains | $8.2 million | $8.0 million |
| Net change in unrealized appreciation | $3.6 million | $21.1 million |
| Increase in net assets from operations | $91.0 million; $0.57 per share | $94.6 million; $0.69 basic per share |
| Net asset value per share | $11.63 | $11.43 at December 31, 2023 |
| Investment portfolio fair value | $3.572 billion | $3.248 billion at December 31, 2023 |
| Debt, carrying value | $1.752 billion | $1.555 billion at December 31, 2023 |
| Cash and cash equivalents | $50.2 million | $98.9 million at December 31, 2023 |
| Distributions | $0.48 per share paid | $0.47 per share paid in Q1 2023 |
Revenue growth reflected higher average loan principal outstanding. Interest and dividend income rose to $115.8 million from $99.9 million; fee income increased to $5.8 million from $5.2 million. Net operating expenses increased to $42.4 million from $39.6 million. The filing does not present conventional operating margins; reported debt-portfolio yields were 14.0% core and 14.9% effective, versus 14.0% and 15.1%, respectively, in Q1 2023.
Operating activities used $240.9 million of cash, compared with $80.9 million used in Q1 2023, largely reflecting increased investment purchases. Financing activities provided $185.5 million, including $403.0 million of debt issuance, $207.0 million of debt repayment, and $67.3 million of common-stock issuance. Cash, cash equivalents, and restricted cash ended the quarter at $60.3 million.
Material changes and portfolio
- Portfolio fair value grew $323.6 million during the quarter. Net debt commitments originated were $772.4 million and net debt fundings were $489.3 million; repayments included $161.1 million of early payoffs.
- Senior secured debt represented 92.7% of portfolio value. Drug discovery and development was the largest industry exposure at 34.3%, followed by software at 23.4%, consumer and business services at 15.1%, and other healthcare services at 13.4%.
- 97.3% of debt investments carried floating rates. The weighted average effective yield declined from 15.3% at year-end to 14.9%; core yield was unchanged at 14.0%.
- Debt investments on non-accrual were 1.2% of portfolio amortized cost, or approximately $42 million, versus 1.0% and $31 million at year-end. The filing identifies Convoy and Better Therapeutics debt as non-accrual; Convoy’s debt was carried at zero fair value.
- Available unfunded commitments increased to $483.4 million from $335.3 million. These commitments may be drawn at portfolio companies’ request, although some commitments may expire undrawn.
- Common shares outstanding rose to 162.2 million from 157.8 million. The company issued 3.7 million shares for $66.4 million net through equity offerings.
Liquidity, leverage, and debt
Management reported $498.1 million of available liquidity, including $50.2 million of cash and borrowing capacity under the MUFG and SMBC facilities and the SMBC letter-of-credit facility. An additional $10.1 million of restricted cash was not included in that figure. Total debt principal was $1.766 billion; $155 million was due within one year, including $105 million of July 2024 notes. Regulatory asset coverage was 218.1% excluding SBA debentures and 206.7% including them. The company reported compliance with all borrowing arrangements.
The company’s debt portfolio is predominantly floating-rate, while most term debt is fixed-rate; $351 million of borrowings under credit facilities were floating-rate. The filing’s annualized sensitivity analysis estimates that a 100-basis-point rate decrease would reduce net income by approximately $20.7 million and EPS by $0.13, while a 100-basis-point increase would raise net income by approximately $26.5 million and EPS by $0.16. These estimates assume no changes in investments or debt.
Management commentary, risks, and unusual items
- Management said the portfolio is positioned to manage current conditions, while noting uncertainty from interest-rate volatility, inflation, market disruptions, geopolitical events, and recession risk. It provided no formal earnings or portfolio guidance in the supplied filing text.
- Q1 realized gains were mainly from selling Palantir and DoorDash equity and warrants and proceeds from Delphix’s acquisition. They were partly offset by write-offs of Proterra, The Faction Group, and ADMA Biologics positions.
- PIK interest income increased to $9.9 million from $5.5 million. PIK is accrued without current cash receipt, but may contribute to taxable income and distributions; the PIK receivable balance was $45.0 million at quarter-end.
- Valuations carry material estimation risk: approximately 96.6% of total assets were investments whose fair value was determined using significant unobservable inputs. Management estimated that a 100-basis-point increase in debt valuation yields would reduce debt-investment fair value by about $44.6 million.
- The six largest individual portfolio exposures each exceeded 5% of net assets; the largest, Axsome Therapeutics, was 8.6%. The ten largest portfolio companies represented 29.9% of portfolio fair value.
- The board declared a further $0.40 base distribution and $0.08 supplemental distribution per share for May 2024. Legal proceedings were described as ordinary-course matters not expected to materially affect results, though future effects cannot be assured. Disclosure controls were reported effective, with no material change in internal control during the quarter.
Important facts for investors to verify
- Whether non-accrual exposures, portfolio-company credit quality, and the $42 million amortized-cost non-accrual balance change in subsequent filings.
- Cash conversion and collectability of accrued income, especially PIK interest and exit fees, alongside the company’s distribution coverage and taxable-income requirements.
- Fair-value assumptions for Level 3 investments, including valuation yields, marks on larger positions, and sensitivity to changes in portfolio-company performance or market conditions.
- Funding needs and liquidity after debt maturities and potential draws against the $483.4 million of available unfunded commitments.
- Effects of rate changes on net investment income, given floating-rate assets, floating-rate credit facilities, and the disclosed sensitivity estimates.
- Share issuance, NAV effects, leverage and asset-coverage ratios, and the company’s ability to sustain its base and supplemental distributions.